The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses
Open accessAbstract
Recent advances in cancer immunology have led to a better understanding of the role of the tumor microenvironment (TME) in tumor initiation, progression, and metastasis. Tumors can occur at many locations within the body and coevolution between malignant tumor cells and non-malignant cells sculpts the TME at these sites. It has become increasingly clear that there are specific differences of the TMEs at different anatomical locations, and these tissue-specific TMEs regulate tumor growth, determine metastatic progression, and impact on the outcome of therapy responses. Herein, we review the scientific advances in understanding tissue-specific TMEs, discuss their impact on immunotherapeutic response, and assess the current clinical knowledge in this emerging field. A deeper understanding of the tissue-specific TME will help to develop effective immunotherapies against tumors and their metastases and assist in predicting clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Moreover, CD8+ T cell density at the tumor margin, a key biomarker of response to anti-PD1 antibodies (74), was significantly lower in the liver metastases cohort compared with those without liver metastases (72).”
BackgroundPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 6×
“The altered ECM results in changes to the tissue architecture and release of soluble molecules and growth factors.”
BackgroundInfluentialImmunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Naba, A., Clauser, K. R., Hoersch, S., Liu, H., Carr, S. A., & Hynes, R. O. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014647 · Cited by 1,354
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Macrophages Regulate the Angiogenic Switch in a Mouse Model of Breast Cancer
Lin, E. Y., Li, J.-F., Gnatovskiy, L., Deng, Y., Zhu, L., Grzesik, D. A., Qian, H., Xue, X.-N., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1278 · Cited by 1,074
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 1×
“The ratio of effector T cells (Eff T cells) to Tregs is associated with response to anti-CTLA-4 checkpoint blockade therapy, where higher Tregs are associated with decreased efficacy (42, 43).”
BackgroundBaseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589
Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in Tumors
Baluk, P., Morikawa, S., Haskell, A., Mancuso, M., & McDonald, D. M. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63540-7 · Cited by 528 · cited 1×
“The abnormalities of blood vessels have been identified in a number of tumor types in murine models, such as spontaneous RIP-Tag2 pancreatic islet tumors, MCA-IV mammary carcinomas, Lewis lung carcinomas (21), 4T1 mammary carcinoma (22), and B16F10 melanoma (23), although studies directly comparing different tumor typ…”
BackgroundCarcinoma‐associated fibroblasts: Non‐neoplastic tumour‐promoting mesenchymal cells
Polanska, U. M., & Orimo, A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24347 · Cited by 208 · cited 1×
“Cancer-associated fibroblasts (CAFs) can secrete protumorigenic molecules including mitogenic growth factors, pro-angiogenic factors, and TGF-β, which alter the TME and support cancer progression (18).”
BackgroundVEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread
Li, X., Padhan, N., Sjöström, E. O., Roche, F. P., Testini, C., Honkura, N., Sáinz-Jaspeado, M., Gordon, E., Bentley, K., Philippides, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms11017 · Cited by 149 · cited 1×
“The abnormalities of blood vessels have been identified in a number of tumor types in murine models, such as spontaneous RIP-Tag2 pancreatic islet tumors, MCA-IV mammary carcinomas, Lewis lung carcinomas (21), 4T1 mammary carcinoma (22), and B16F10 melanoma (23), although studies directly comparing different tumor typ…”
BackgroundIL-22 controls iron-dependent nutritional immunity against systemic bacterial infections
Sakamoto, K., Kim, Y.-G., Hara, H., Kamada, N., Caballero-Flores, G., Tolosano, E., Soares, M. P., Puente, J. L., Inohara, N., & Núñez, G. (2017) · Science Immunology · doi:10.1126/sciimmunol.aai8371 · Cited by 127
Cited by
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“Due to the compelling role of TME in malignancy, many efforts are focused on this area [15, 16] .”
BackgroundMartinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 540
Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response
Hu, F.-F., Liu, C.-J., Liu, L.-L., Zhang, Q., & Guo, A.-Y. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa176 · Cited by 354
Metadata
- Authors
- Oliver, A. J., Lau, P. K. H., Unsworth, A. S., Loi, S., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-01-31
- Volume
- 9
- Pages
- 70-70
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2792583114
- Cited by
- 169
- References
- 20
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.